These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 37497166)
21. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. Li N; Wang J; Zhan X Front Immunol; 2021; 12():752643. PubMed ID: 34887858 [TBL] [Abstract][Full Text] [Related]
22. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. Li N; Li Y; Zheng P; Zhan X Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015 [TBL] [Abstract][Full Text] [Related]
23. Pan-cancer analysis reveals the relationship between RCSD1 immune infiltration and clinical prognosis in human tumors. Qiao H; Yin H; Feng Y; Tang H Front Immunol; 2022; 13():1008778. PubMed ID: 36311703 [TBL] [Abstract][Full Text] [Related]
24. Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma. Zheng M; Liu J; Bian T; Liu L; Sun H; Zhou H; Zhao C; Yang Z; Shi J; Liu Y Int Immunopharmacol; 2021 Jan; 90():107134. PubMed ID: 33168407 [TBL] [Abstract][Full Text] [Related]
25. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates. Fan K; Zhang BH; Han D; Sun YC BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494 [TBL] [Abstract][Full Text] [Related]
26. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma. Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123 [TBL] [Abstract][Full Text] [Related]
27. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer. Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525 [TBL] [Abstract][Full Text] [Related]
28. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes. Fang X; Li D; Wan S; Hu J; Zhang P; Jie D; Chen L; Jiang G; Song N J Gene Med; 2024 Jun; 26(6):e3694. PubMed ID: 38847309 [TBL] [Abstract][Full Text] [Related]
29. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma. Guo L; Li X; Liu R; Chen Y; Ren C; Du S Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817 [TBL] [Abstract][Full Text] [Related]
30. SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma. Zhang X; Wu Z; Ma K BMC Cancer; 2022 Apr; 22(1):406. PubMed ID: 35421944 [TBL] [Abstract][Full Text] [Related]
31. Identification of RNMT as an immunotherapeutic and prognostic biomarker: From pan-cancer analysis to lung squamous cell carcinoma validation. Huang S; Tan C; Zheng J; Huang Z; Li Z; Lv Z; Chen W; Chen M; Yuan X; Chen C; Yan Q Immunobiology; 2024 Sep; 229(5):152836. PubMed ID: 39018675 [TBL] [Abstract][Full Text] [Related]
32. Correlation between metastasis-associated gene 1 expression and tumor-associated macrophages in non-small cell lung cancer. Ma K; Li YX; Guo QQ Neoplasma; 2022 Sep; 69(5):1092-1100. PubMed ID: 35951452 [TBL] [Abstract][Full Text] [Related]
33. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index. Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C Front Immunol; 2023; 14():1236444. PubMed ID: 37841237 [TBL] [Abstract][Full Text] [Related]
34. The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases. Liang Y; Lei Y; Du M; Liang M; Liu Z; Li X; Gao Y J Cell Mol Med; 2021 Jul; 25(14):7039-7051. PubMed ID: 34117717 [TBL] [Abstract][Full Text] [Related]
35. Identification of NR3C2 as a functional diagnostic and prognostic biomarker and potential therapeutic target in non-small cell lung cancer. Sun YY; Gao HC; Guo P; Sun N; Peng C; Cheng ZH; Gu J; Liu JY; Han F Cancer Innov; 2024 Aug; 3(4):e122. PubMed ID: 38948253 [TBL] [Abstract][Full Text] [Related]
36. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation. Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014 [TBL] [Abstract][Full Text] [Related]
37. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2. Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y Front Immunol; 2023; 14():1155182. PubMed ID: 37275857 [TBL] [Abstract][Full Text] [Related]
38. ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinoma. Yang W; Chen K; Yu Q; Liao R; He H; Peng Y; Yang Z; Zhang X Cancer Med; 2023 Jul; 12(13):14820-14832. PubMed ID: 37162299 [TBL] [Abstract][Full Text] [Related]
39. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis. Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ Front Immunol; 2021; 12():724741. PubMed ID: 34335635 [TBL] [Abstract][Full Text] [Related]
40. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma. Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L Front Immunol; 2021; 12():723172. PubMed ID: 34539658 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]